BLOG
Hidden Gem - Piramal Pharma
Piramal is one of the largest Indian CDMO players with vertically integrated model and assets spread across India and regulated markets.
In CDMO, the company over the years have been focusing on high value services- 1) more focus towards catering to innovators, 2) offering of differentiated services such as high potency APIs, Antibody drug conjugates (ADC), peptides among others and 3) offering of integrated services platform leveraging on global manufacturing network. We believe the emerging global tailwinds are important external factors besides improving fundamentals.
Based on strong visibility and capacities, the company has given upbeat guidance with CDMO revenues to be around US$ 1.2 billion (CAGR of ~13%) with 25% EBITDA margins leveraging on its globally diversified network of facilities across 3 continents by 2030. Note that this guidance excludes possible positive / negative implications from the Biosecure Act.
In complex hospital generics, the company aspires to reach US$ 600 million revenues (CAGR of ~13%) with 25%+ EBITDA margins and in ICH segment the company aims to scale up revenues at a 9% CAGR to US$ 200 million in the next six years and achieve double-digit EBITDA margins by optimizing expenses.
We value PPL at ₹ 280 based on SoTP valuations, i.e. 23x FY26E CDMO EBITDA, 18x FY26E CHG EBITDA, 1.5x FY26E Consumer Healthcare Sales and 10x PAT from AbbVie JV.
Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Related content
Blogs
Articles - Stocks
Advantages and Disadvantages of NPS
It is a long established fact that a reader will be distracted by the readable content of a page when looking at it...
Articles - Stocks
Advantages and Disadvantages of NPS
It is a long established fact that a reader will be distracted by the readable content of a page when looking at it...
Articles - Stocks
Advantages and Disadvantages of NPS
It is a long established fact that a reader will be distracted by the readable content of a page when looking at it...
Video
Video - Stocks
What is Book Value?
Book Value Explained – Find out what is book value in stocks in this video by ICICIdirect.com.
Video - Stocks
What is Book Value?
Book Value Explained – Find out what is book value in stocks in this video by ICICIdirect.com.
Video - Stocks
What is Book Value?
Book Value Explained – Find out what is book value in stocks in this video by ICICIdirect.com.